The Quantellect read.As of Nov 19, 2026, 5 active firms cover Entera Bio Ltd: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $9.00 to $11.00, so the covering firms are broadly aligned. The average target of $9.75 sits 198% above the current $3.27. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.75
+198.2% upside
Average target across 4 active firms as of Nov 19, 2026 vs $3.27 current
Highest Target$11.00
Average Target$9.75
Lowest Target$9.00
Detailed analyst forecasts for ENTX
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate ENTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ENTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.13 – $-0.12 · 2 analysts · +79% YoY
Next period, 2 analysts expect Entera Bio Ltd to earn $-0.13 a share (range $-0.13 – $-0.12), versus $-0.07 a year earlier. Full-year consensus is $-0.47, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Entera Bio Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENTX.
#1
Vamil Divan
Guggenheim · Rank #211
Buy
$11.00+236.4% to target
Overall win rate
48%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$9.00+175.2% to target
Overall win rate
36%
+ Follow
#3
PD
Patrick Dolezal
LifeSci Capital
Buy
$10.00+205.8% to target
Coverage
—
+ Follow
#4
David Risinger
Leerink Partners
Buy
$9.00+175.2% to target
Coverage
—
+ Follow
#5
RS
Ram Selvaraju
H.C. Wainwright
Buy
$9.00+175.2% to target
Coverage
—
+ Follow
ENTX stock forecast FAQ
What is ENTX's average 12-month price target?+
The 4 active firms with a live target average $9.75 for Entera Bio Ltd over the next 12 months, ranging from a $11.00 high to a $9.00 low, as of Nov 19, 2026.
Is ENTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ENTX?+
The Street-high target is $11.00 (Guggenheim), and the Street-low is $9.00 (Leerink Partners). The average of all 4 active-firm targets is $9.75.
How many active Wall Street firms cover ENTX?+
5 active firms have a recognized rating on Entera Bio Ltd as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ENTX?+
Among analysts who currently cover ENTX, Vamil Divan of Guggenheim has the strongest overall Quantellect track record (Rank #211). Their current call is Buy with a $11.00 target.
What is Entera Bio Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.13 – $-0.12) across 2 analysts. Full-year EPS is projected at $-0.47, rising to $-0.44 the following year.
How much revenue is Entera Bio Ltd expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ENTX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate ENTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.